Matulionyte R, Rohner P, Uçkay I, Lew D, Garbino J
Division of Infectious Diseases, Department of Internal Medicine, University of Geneva Hospitals, 1211Geneva, Switzerland.
J Clin Pathol. 2004 Aug;57(8):807-12. doi: 10.1136/jcp.2004.016923.
To assess the incidence of nocardia infection over 15 years in a tertiary care hospital.
Over a 15 year period, Nocardia spp were isolated from 20 patients hospitalised at the Geneva University Hospitals, Switzerland.
Sixteen patients had one or more underlying conditions. The median time between symptom onset and diagnosis was 30 days. The most common initial unconfirmed diagnosis was pulmonary tuberculosis (four). The lung was involved in 16 cases, followed by the central nervous system (two) and skin (two); one patient had disseminated infection. The most common species identified was N asteroides. In vitro susceptibility testing was performed on 14 of 20 strains. All strains were susceptible to imipenem and amikacin. Initial treatment with trimethoprim/sulfamethoxazole (TMP/SMX) was started in 14 patients, although five patients had to be switched to another treatment because of side effects or lack of efficacy. A cure was observed in 15 patients, death in three, and relapse or complications in two.
Nocardiosis can become a severe infection and mainly affects profoundly immunocompromised patients. Differential diagnosis often delays the time to diagnosis, which worsens the outcome. New diagnostic tools, such as the polymerase chain reaction, could provide more rapid and reliable results. TMT/SMX was the most commonly prescribed treatment, but needed to be changed for another treatment because of side effects or lack of efficacy in a considerable proportion of patients. Imipenem should be used as an alternative treatment for severely ill patients, and the sulfa combination for less severe infections.
评估一家三级护理医院15年间诺卡菌感染的发生率。
在15年期间,从瑞士日内瓦大学医院住院的20例患者中分离出诺卡菌属。
16例患者有一种或多种基础疾病。症状出现至诊断的中位时间为30天。最常见的初始未确诊诊断是肺结核(4例)。肺部受累16例,其次是中枢神经系统(2例)和皮肤(2例);1例患者有播散性感染。鉴定出的最常见菌种是星形诺卡菌。对20株菌株中的14株进行了体外药敏试验。所有菌株对亚胺培南和阿米卡星敏感。14例患者开始使用甲氧苄啶/磺胺甲恶唑(TMP/SMX)进行初始治疗,尽管5例患者因副作用或缺乏疗效而不得不改用其他治疗。15例患者治愈,3例死亡,2例复发或出现并发症。
诺卡菌病可成为严重感染,主要影响免疫功能严重低下的患者。鉴别诊断往往会延迟诊断时间,从而使预后恶化。新的诊断工具,如聚合酶链反应,可提供更快速可靠的结果。TMT/SMX是最常用的处方治疗药物,但相当一部分患者因副作用或缺乏疗效而需要改用其他治疗。亚胺培南应用于重症患者的替代治疗,磺胺类药物联合应用于病情较轻感染的治疗。